← Back to Clinical Trials
Recruiting NCT07496853

NCT07496853 Effect of Upper Extremity Support on Spatiotemporal Parameters of Gait in Individuals With Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07496853
Status Recruiting
Phase
Sponsor Ankara Yildirim Beyazıt University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 34 participants
Start Date 2026-04-01
Primary Completion 2026-12-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
C-Mill VR+ (Force-plate integrated treadmill)No Support ProtocolUnilateral Support Protocol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 34 participants in total. It began in 2026-04-01 with a primary completion date of 2026-12-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Purpose: The primary goal of this study is to investigate how different levels of upper extremity (arm) support affect walking patterns in individuals who have experienced a stroke. Specifically, the research aims to determine how restricting or facilitating arm swing during walking modulates spatiotemporal gait parameters (such as speed, step length, and rhythm). Background: Arm swing plays a crucial role in maintaining balance, stability, and energy efficiency during normal walking. Following a stroke, many patients use walking aids (like canes or walkers) or clinical supports (like parallel bars) that restrict natural arm movement. This study examines whether these restrictions significantly alter gait mechanics in the stroke population. Methodology: Participants will participate in a cross-over experimental trial. Each participant will walk on a specialized treadmill system (C-Mill VR+) under three randomized conditions: 1. Unsupported walking (no arm support), 2. Single-arm support (using the non-paretic side), 3. Dual-arm support (using both arms). Researchers will record gait speed, step length, cadence, and duration of stance/swing phases for each condition. Expected Outcome: The findings will provide scientific evidence on how different support strategies modulate walking performance. This information will help physical therapists design more effective, individualized rehabilitation programs to improve mobility and quality of life for stroke survivors.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of hemiplegia with ICD-10 code G.81. * Presence of unilateral hemiplegia. * No medical contraindications for the use of assistive devices (e.g., cane, tripod). * Aged 18 years or older. * Ability to walk for at least 2 consecutive minutes. Exclusion Criteria: * Presence of aphasia. * Recurrent stroke. * Montreal Cognitive Assessment (MoCA) score below 10 points.

Contact & Investigator

Central Contact

Murat AKINCI

✉ muratakinci.fzt@gmail.com

📞 +90 552 935 69 78

Frequently Asked Questions

Who can join the NCT07496853 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07496853 currently recruiting?

Yes, NCT07496853 is actively recruiting participants. Contact the research team at muratakinci.fzt@gmail.com for enrollment information.

Where is the NCT07496853 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT07496853 clinical trial?

NCT07496853 is sponsored by Ankara Yildirim Beyazıt University. The trial plans to enroll 34 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology